|
|
|
|
| |
|
|
About Primm
Activities
The main company's activities are briefly summarized here.
Biotechnology services
During its first ten years of life, Primm has become the leading Italian company in the area of biotechnology services, and several qualified industrial and academic laboratories in Europe and the United States have chosen Primm as their partner for selected biotechnological services.
In order to stay at the forefront of the technological and scientific evolution of research activities, Primm is always investing in new technical processes and in the automation of the manufacturing steps.
Through our internal know-how, and a broad and heterogeneous portfolio of research tools and services, we can efficiently complement the research activities of the customers, providing reliable and cost-effective technical solutions.
Research and development
Primm has grown not only as a service company but, having a strong experience in industrial R&D, it has also invested its own resources in selected projects with potential industrial outcome.
Through Primm's efforts, specific projects are brought to an appropriate level of maturation where joint ventures with larger industrial partners can be established.
In the past few years, several R&D projects in different areas have been carried out in close collaboration with important Italian and international companies and academic institutions. Peptides are used to investigate problems such as the ligand-receptor interactions or to study the tridimensional structure of specific protein domains.
In many cases, it is also possible to design synthetic peptides which display the same or similar biochemical and biological properties.
With this respect, one of Primm's main focus has been the design, synthesis and pharmaceutical development of novel bioactive peptides for various therapeutical applications.
Computer-assisted molecular modelling is used to gain structural information and to design novel and innovative peptide molecules, which could display a desired biological activity for further pharmaceutical development.
Some of these projects have led to the filing and acquisition of relevant patents and now are in pre-clinical phases. Peptides have a broad range of potential clinical benefits, with applications in some of the most dire and prevalent disase categories. At present, Primm's main therapeutic areas of interests are in inflammation, asthma and infectious diseases.
Another relevant area of R&D activity is related to the development of recombinant strains and technologies for the industrial production of biopharmaceuticals, which is also performed in collaboration with important industrial partners. In the last few years, Primm has developed efficient technologies for the manufacturing of selected recombinant proteins in heterologous systems. |
|
|
